Key clinical point: Financial disclosure statements in published oncology studies are often incomplete.
Major finding: Among study authors involved in oncology trials, 32% did not fully disclose payments from trial sponsors.
Study details: A comparison of financial disclosure statements in published studies with information from the Open Payments database. The researchers looked at studies that supported U.S. oncology drug approvals from Jan. 1, 2016, to Aug. 31, 2017.
Disclosures: The researchers reported having no financial disclosures.
Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Practice Management
Many believe tumor profiling will benefit present treatment, Marron et al. JCO Precis Oncol. 2019 Jan 22. doi: 10.1200/PO.18.00176.
Physician mothers with extra caregiving at home at higher risk, Yank V et al. JAMA Internal Medicine. 2018 Jan 28. doi: 10.1001/jamainternmed.2018.6411.
Over half of Americans support Medicare for All, Kaiser Family Foundation Health Tracking Poll – January 2019
Uninsured rate could rise with proposed premium calculator, Federal Register (84 FR 227)
No difference in financial distress with counseling intervention , Kircher SM et al. J Oncol Pract. 2019 Jan 9. doi: 10.1200/JOP.18.00270.